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Abstract
Genome-wide association studies have identified over 70 single-nucleotide polymorphisms (SNPs) associated with breast
cancer. A subset of these SNPs are associated with quantitative expression of nearby genes, but the functional effects of the
majority remainunknown.Wehypothesized that some risk SNPsmay regulate alternative splicing. Using RNA-sequencing data
from breast tumors and germline genotypes from The Cancer Genome Atlas, we tested the association between each risk SNP
genotype and exon-, exon–exon junction- or transcript-specific expression of nearby genes. Six SNPs were associated with
differential transcript expression of seven nearby genes at FDR < 0.05 (BABAM1, DCLRE1B/PHTF1, PEX14, RAD51L1, SRGAP2D and
STXBP4). We next developed a Bayesian approach to evaluate, for each SNP, the overlap between the signal of association with
breast cancer and the signal of association with alternative splicing. At one locus (SRGAP2D), this method eliminated the
possibility that the breast cancer risk and the alternate splicing event were due to the same causal SNP. Lastly, at two loci, we
identified the likely causal SNP for the alternative splicing event, and at one, functionally validated the effect of that SNP on
alternative splicing using a minigene reporter assay. Our results suggest that the regulation of differential transcript isoform
expression is the functional mechanism of some breast cancer risk SNPs and that we can use these associations to identify
causal SNPs, target genes and the specific transcripts that may mediate breast cancer risk.
Introduction
Genome-wide association studies (GWASs) have identified thou-
sands of disease risk-associated single-nucleotide polymorph-
isms (raSNPs), including, to date, 75 that are associated with
breast cancer risk (1). The vast majority of raSNPs are located in
noncoding regions of the genome; therefore, they, or SNPs in link-
age disequilibrium (LD) with them, are likely to influence risk by
affecting the regulation of nearby genes or noncoding RNAs (2,3).
To determine their function, investigators have tested their asso-
ciation with expression levels of nearby genes (expression quan-
titative trait loci, or eQTLs) in cis (4–7) or in trans (4) and assessed
whether SNPs in LD with the index raSNP demonstrate evidence
for transcription factor binding or histone methylation (6,8).
These methods have uncovered eight eQTL associations (4,7),
three associations with the targets of a nearby transcription
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factor (4) and an enrichment of FOXA1 and ESR1 enhancer-bind-
ing sites within the raSNP loci (8).
Another, yet unexplored, mechanism by which raSNPs may
affect regulation of nearby genes is through post-transcriptional
regulation, such as alternative splicing. Previous work has used
genome and transcriptome data from lymphoblastoid cell lines
to systematically search for germline variants associated with
the expression level of a specific transcript isoform of a gene
(9–11). These genome-wide analyses have identified hundreds
of splicing quantitative trait loci (splicing QTLs), typically exonic
or intronic variants that affect exon skipping, alternative splice
site inclusion, or the gene’s 5′ or 3′ end sequence (9–11). GWAS
variants are modestly enriched for splicing QTLs as well as for
eQTLs (9), suggesting that some raSNPs may affect risk by affect-
ing differential transcript expression.
Modification of alternative splicing is known to be important
in cancer development (12) and the epithelial-mesenchymal
transition (13), and recent work has shown that somatic muta-
tions affecting splicing can act as driver mutations in tumors
(14). However, no systematic analysis has examined germline
variants affecting cancer risk to identify, which may affect alter-
native splicing. In this paper, we develop methods to query
whether a specific raSNP functions as a splicing QTL of a nearby
gene. Using publicly available data from The Cancer Genome
Atlas (TCGA) (15), we perform a focused analysis of breast cancer
raSNPs, discovering five risk loci that may mediate risk by affect-
ing differential transcript isoform expression.
Results
Splicing QTL analysis of breast cancer raSNPs
We used the RNA-sequencing (RNA-seq) data and matched
germline genotypes for 358 estrogen receptor (ER)-positive breast
tumors and 109 ER-negative breast tumors from TCGA. For each
of the breast cancer raSNPs, we searched for differential tran-
script isoform expression of nearby genes (Supplementary
Material, Table S1), adjusting for overall gene expression, global
expression variability (16,17) and genetic ancestry. We used
three complementary approaches, testing the association
between raSNPs and (1) rank-normalized reads per kilobase per
million mapped reads (RPKM) mapping to each exon, (2) rank-
normalized reads per million mapped reads (RPM) mapping to
each exon–exon junction and (3) rank-normalized expression
estimates of reconstructed transcripts of each annotated iso-
form, as generated by the RSEMalgorithmusing UCSC transcripts
(chosen as its output is available through TCGA) (3) (Supplemen-
taryMaterial, Tables S2–S4).We identified 13 associationswith 10
raSNPs using thesemethods at FDR < 0.05, including 9 exon asso-
ciations, 8 junction associations and 6 whole-transcript associa-
tions; several splicing QTLs were identified by more than one
approach (Fig. 1). Q–Q plots showed deviation from normality at
the extremes of the P-value distributions (Supplementary Mater-
ial, Fig. S1). When the analysis was repeated in the smaller set of
ER-negative tumors, we identified four associations with four
raSNPs, including two exon associations, two junction associa-
tions and two transcript associations (Supplementary Material,
Table S5), all of which were also identified in the ER-positive
tumors.
For the exon-specific test, we also tested for differences in raw
counts mapping to each exon, using the negative binomial distri-
bution as implemented by the DEXSeq R Bioconductor software
package V1.8.0 (18). Of the nine SNP-gene exon associations iden-
tified using rank-normalized RPKM values, seven were significant
at FDR < 0.05 when using DEXSeq, although the methods identi-
fied differing numbers of exons as significant (Supplementary
Material, Table S6). One additional exon association (DCLRE1B)
identified with rank-normalized RPKM values was captured be-
cause our test adjusted for overall gene expression with the exon
of interest excluded, rather than because of a difference between
rank-normalized RPKM values/linear regression versus raw
counts/the negative binomial distribution. Given the similarity of
the results, we used only normalization and linear regression for
the remainder of the analyses.
We next excluded associations that could have resulted from
one of three possible sources of error (Fig. 1). Associations identi-
fied through whole-transcript reconstruction require a high level
of scrutiny because of inherent inaccuracies in transcript assem-
bly, underscored by inconsistency in results fromdifferentmeth-
ods (19). We therefore required associations identified through
whole-transcript reconstruction to be supported by significant
exon- or junction-specific associations, excluding one associ-
ation (rs3817198-MOB2) that was not consistent with any exon-
or junction-specific event at even a nominal level of significance.
In contrast, the rs8170-BABAM1 association, also identified
through whole-transcript reconstruction, was supported by
increased expression of one exon 1–2 junction (P = 1.9 × 10−4)
and decreased expression of another that used an alternate 3′
acceptor site (P = 0.024).
Figure 1. Flowchart for determining splicing QTL associations. We identified 13
SNP-gene associations through exon, junction and whole-transcript association
tests with risk-associated SNPs; several associations were identified by multiple
methods. After excluding SNP-gene associations that could not be corroborated
with other tests, that could be related to the presence of pseudogenes or
paralogs or that could have derived from mapping bias to the reference
genome, seven SNP-gene associations remained.
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We excluded four associations (two raSNPs) because the gene
of interest had a paralog or pseudogene in another part of
the genome. If a read can map to two different sections of the
genome, the mapping algorithm’s inaccuracy in placing it cor-
rectly can generate bias exacerbated by genetic variation (20).
Rs720475 was identified as a splicing QTL for three genes: ARH-
GEF5, OR2A7 and OR2A9P. ARGHEF5 and OR2A7 are near-identical
homologs; in a recent annotation of the genome [Gencode V19
(21)], OR2A7 has been extended and labeled ARHGEF34P. Similar-
ly, OR2A9P is included in this region and represented by two
pseudogenes 40 kB apart. Thus, the associations between
rs720475 and expression of these three genes at least in part
reflected difficulties in mapping reads that could come from
multiple genes. The associations between rs4808801 and SSBP4
exons 2–4 were also excluded because of the presence of a retro-
transposed pseudogene of SSBP4 on chromosome 18.
Finally, we excluded one association because of evidence of
mapping bias to the reference genome. Mapping algorithms suc-
cessfully map RNA-seq reads containing the reference allele
more frequently than reads containing the alternate allele (22);
eQTL and splicing QTL analyses may be susceptible to this bias
if the exons contain SNPs in LD with the index raSNP. Four of
the splicing QTL loci (including SSBP4, already excluded because
of the presence of a pseudogene) contained an SNP in LDwith the
index raSNP (r2 > 0.1) within the associated exon or junction. For
each of these loci, we recalculated the association excluding all
reads that mapped across such SNPs (Supplementary Material,
Table S7). The associations between rs6504950 and STXBP4 and
between rs11552449 and DCLRE1B remained significant. How-
ever, the associations between rs3903072 and MUS81 were not
significant when excluding the reads that mapped to a pair of
SNPs, rs659857 and rs545500. These SNPs are located two base
pairs apart in MUS81 exon 6 and are in perfect LD with each
other, an unusual situation that increases the potential for
mapping bias.
After excluding the six problematic associations, six raSNPs
were associated with exon, junction or whole-transcript expres-
sion of seven genes (Table 1). Four of the six loci replicated at
P < 0.05 in the smaller set of 109 ER-negative tumors from TCGA
(Table 1), three at FDR < 0.05. We identified one SNP associated
with exon skipping (rs11552449-DCLRE1B), two SNPs associated
with alternative splice site usage (rs6504950-STXBP4 and
rs8170-BABAM1) (Figs 2 and 3), three SNPs associated with more
complex exon usage patterns (rs11552449-PHTF1, rs616488-
PEX14 and rs999737-RAD51L1) and one SNP associated only
with an exon–exon junction, which could represent an unanno-
tated alternative splice site or other unannotated pattern of exon
usage (rs11249433-SRGAP2D).
Relationship between breast cancer risk association
and splicing QTL association
Because eQTLs and splicing QTLs are common throughout the
genome (9,10,26), it is plausible that a raSNP could be associated
withnearby gene or transcript expression but that this association
would not be connected to breast cancer. To assess the possibility
that the causal SNPs for the splicing QTL and the breast cancer as-
sociation were different, we calculated the posterior probabilities
of each of the SNPs at the locus as the causal SNP for each of the
two traits. For the trait of breast cancer risk, we used association
statistics from the GAME-ONwebsite (http://gameon.dfci.harvard.
edu). We then identified the most parsimonious list of SNPs that
produced a cumulative posterior probability of >0.95 for the breast
cancer association (Table 2). We then compared the cumulative
posterior probability of the splicing QTL associations for the
same set of SNPs. We also repeated the inverse analysis, identify-
ing themost parsimonious list of SNPs that produced acumulative
posterior probability of ≥0.95 of the splicing QTL association and
found the cumulative posterior probability of the GWAS associ-
ation from the GAME-ONdata (SupplementaryMaterial, Table S9).
For some of the loci, such as STXBP4, SRGAP2D and RAD51L1,
the breast cancer association is highly significant and thus the
number of likely SNPs is relatively small. For the STXBP4 locus,
we were able to narrow the list of SNPs at the locus from 908 to
40 and noted a very high probability (0.99) that the splicing QTL
causal variant was also captured in this set. Conversely, starting
with the splicing QTL, we narrowed the SNPs down to 23 and
found a posterior probability of 0.55 that the GWAS causal variant
was also captured in this set. For the SRGAP2D locus, startingwith
the GWAS data, we narrowed the list of likely SNPs from 37 to 3,
and the posterior probability that the splicing QTL was deter-
mined by these three SNPs was 4 × 10−7. Conversely, starting
with the splicing QTL data, we only narrowed down the list of
SNPs from 37 to 23 but still found that the posterior probability
of the causal SNP for GWAS was ∼0.01. Thus, we excluded the
possibility that the splicing QTL and breast cancer association
are caused by the same variant at this locus. For RAD51L1, wenar-
rowed the list of likely SNPs at the locus from 1152 to 11, and the
posterior probability of the 11 SNPs for the splicing QTL was 3 ×
10−9. Similarly, starting with the splicing QTL, we narrowed the
signal to five SNPs which had a posterior probability of the
GWAS SNP of ∼1 × 10−9. Therefore, we also excluded the possibil-
ity that the case–control and exon 15 splicing QTL effect are
caused by the same variant. Interestingly, when examining the
association of each individual exon of the gene with the raSNP
(Supplementary Material, Fig. S2), we noted that the raSNP for
RAD51L1 was associated with several different exons, though
only exon 15 at FDR < 0.05. In the reconstructed transcript test,
the raSNP for RAD51L1was also associated (P = 7.3 × 10−4), though
not at FDR < 0.05, with transcript uc001xkf, which includes exon
14 rather than exon 15. This transcript had greater overlap of the
posterior probability with the breast cancer association. This
analysis suggests that it may be possible to use this Bayesian ap-
proach to disentangle not only whether the causal SNP for a spli-
cing QTL and for breast cancer risk are the same but more
precisely which transcript is in fact associated with breast cancer
risk.
At other loci, the breast cancer association statistics were less
significant and consequently our ability to narrow down the set
of plausible SNPs, and to dissect the splicing QTL association
from the breast cancer association, was more limited. We note
that at the PEX14 locus, the overlap with the posterior probability
for breast cancer was higher for transcript uc001arm than for
exon 7, hinting at the possibility that it is this entire transcript ra-
ther than simply exon 7 that is implicated in breast cancer risk. At
the DCLRE1B/PHTF1 locus, we were unable to definitively rule out
one of those genes when we examined the overlap with the pos-
terior probability of breast cancer. Similarly, the posterior prob-
ability at the BABAM1 locus included a large number of SNPs
that we could not narrow effectively based on the breast cancer
association.
Leveraging splicing QTLs to identify causal SNPs
Once a raSNP is identified through GWAS, a major challenge is
discerning which of the many possible SNPs in LD with the ini-
tially identified SNP might be causal (2). The link between the
raSNP and the expression of a particular splice junction or exon
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Table 1. Splicing QTLs identified in ER-positive tumors at FDR < 0.05, after exclusions
SNP rsID Gene β (ER+) P-value (ER+) FDR (ER+) P-value (ER−) Predicted splicing pattern associated with breast cancer risk
Component
rs6504950 STXBP4 Longer exon 6 (6 bp 5′): ↑ use of 3′ acceptor site at chr17:53 076 993
and ↓ use of chr17:53 076 987
Exon 5:6 junction 1 −0.73 5.5E− 24 8.3E− 20 1.9E− 11
Exon 5:6 junction 2 0.59 1.9E− 23 1.4E− 19 1.6E− 07
Transcript uc010dcc −0.42 3.5E− 11 4.4E− 08
rs11552449a DCLRE1B ↑ exon 2 inclusion
Transcript uc001eei −0.64 8.6E− 14 1.6E− 10 2.4E− 06
Transcript uc001eeg 0.26 2.2E− 10 2.3E− 07 4.4E− 05
Exon 1:3 junction −0.48 7.0E− 08 4.5E− 05 4.5E− 03
Exon 2 0.24 2.7E− 08 2.1E− 05 6.1E− 06
rs8170 BABAM1 Longer exon 2 (38 bp 5′): ↑ use of 3′ acceptor site at chr19:17 379 565
Transcript uc002nfv 0.47 3.0E− 08 2.1E− 05 8.2E− 06
Transcript uc002nfu −0.29 2.7E− 07 1.7E− 04 0.038
rs11249433 SRGAP2D b
Exon 2:3 junction −0.39 1.3E− 08 1.2E− 05
rs11552449a PHTF1 ↑ inclusion of exons 1 and 2
Exon 1:2 junction 0.47 3.0E− 08 2.1E− 05
Exon 2 0.28 1.9E− 06 9.0E− 04
rs616488 PEX14 ↓ transcript uc001arm (exons 1, 2, 6, 7)
Exon 7 −0.39 3.8E− 07 2.2E− 04 0.021
Transcript uc001arm −0.39 5.1E− 07 2.8E− 04
rs999737 RAD51L1 ↓ transcript uc001xkf (exons 1–11, exon 14)
Exon 15 −0.33 2.3E− 05 9.1E− 03
β is for the effect of the breast cancer risk allele on the gene component.
bp, base pairs.
Transcripts are named according to UCSC ID. Genomic positions are for hg19 build.
P-values for ER-negative tumors displayed when is <0.05.
aSNP is associated with transcript expression of two different genes.
bSplicing QTL association not predicted to be linked to breast cancer given pattern of association at locus.
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can shed new light on the identity of the causal SNP, as in some
cases only one or a few SNPs in LDwith the original raSNPmay be
likely able to affect alternative splicing by virtue of their location
within the gene. Examining all known variants from 1000 Gen-
omes in each splicing QTL region, we were able to narrow the
list of possible functional SNPs for three of the six splicing QTLs
predicted to be associated with breast cancer (Supplementary
Material, Table S8).
In two cases, the association of the raSNP with alternative
splice site usage allowed us to identify the specific likely causal
SNP. At the STXBP4 locus, rs6504950 was associated with
increased usage of one 3′ acceptor site of intron 5 of STXBP4
and decreased usage of another that was six bases distant
(Fig. 2). Of 177 SNPs in LD with rs6504950 at r2 > 0.6, only one
(rs11658717) was in intron 5, where it altered an AG 3′ acceptor
site to AA; as expected, with the G allele, virtually all transcripts
appeared to use the first of the two possible 3′ acceptor sites,
whereas with the A allele, virtually all transcripts appeared to
use the second. Interestingly, not only was rs11658717 more as-
sociated with the exon 5–6 junctions than was rs6504950, it was
also modestly more associated with breast cancer risk (Supple-
mentary Material, Table S8) (27).
Similarly, rs8170 was associated with increased usage of one
3′ acceptor site in intron 1 of BABAM1 and decreased usage of
another. Of 34 SNPs in LD with rs8170 at r2 > 0.6, only one was
located in the first intron (Fig. 3). This SNP, rs10424178, lies within
Figure 2.Alternative splice site usage in STXBP4 exon 6 based on rs6504950 genotype. (A)With the rs6504950 risk allele, virtually all STXBP4 exon 5–6 junction readsmap to
one junction, whereas with the non-risk allele, virtually all map to the other. (B) LocusZoom plot (23) displaying −log10 P-values for the association of each SNPwithin the
window with STXBP4 exon 5–6 junction 1 by position. (C) The locus of rs11658717, the presumed causal SNP. The two alternative 3′ splice sites are highlighted in red. The
minor allele of rs11658717 (G) is in high LD with the risk allele of rs6504950 (A). Screenshot from http://genome.ucsc.edu (24).
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the predicted branch point sequence (25) for the second 3′ acceptor
site and is 5 bases 3′ of the first 3′ acceptor site. Like rs11658717,
rs10424178 was more strongly associated than the index raSNP
with the transcript expression (Supplementary Material, Table S8);
data for its association with breast cancer risk were not available.
To test whether the alteration of the branch point sequence
by rs10424178 caused the predicted splicing difference in vitro,
we cloned the BABAM1 exon 2 and flanking intronic sequence
into twominigene plasmid vectors, each containing an alternate
allele of rs10424178, transfected each vector into cells and
Figure 3. Alternative splice site usage in BABAM1 exon 2 based on rs8170 genotype. (A) Relative expression of RSEM reconstructed BABAM1 transcript uc002nfu decreases
and uc002nfv increases with rs8170 risk genotype. (B) LocusZoom plot (23) displaying −log10 P-values for the association of each SNP within the window with BABAM1
uc002nfv transcript expression by position. (C) Locations of all candidate SNPs, defined as SNPs with r2 > 0.6 with rs8170, or LD unknown but splicing QTL association
P-value of <1 × 10−6. SNPs are colored red if r2 > 0.8 and orange if r2 > 0.6. Screenshot from http://genome.ucsc.edu (24). (D) The locus of rs10424178, the presumed
causal SNP. The two alternative 3′ splice sites are highlighted in red, and the two alternative branch points as identified by Human Splicing Finder (25) are highlighted
in blue. The minor allele of rs10424178 (T) is in high LD with the risk allele of rs8170. Screenshot from http://genome.ucsc.edu (24). (E) Results of a six replicates of a
minigene reporter vector assay, transfecting the major allele (C) or minor allele (T) of rs10424178. In each well, the lower band represents the shorter BABAM1 exon 2,
as included in transcript uc002nfu, and the upper band represents the longer BABAM1 exon 2, as included in transcript uc002nfv; the identities of the bands were
confirmed by sequencing. The percentages shown below each well are the intensity of the lower band divided by the sum of the intensities of the lower band and the
upper band. In all six replicates, the percentage of the total bands represented by the shorter BABAM1 exon 2 is higher for the major allele than that for the minor
(risk) allele.
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measured the gel band intensity of the two BABAM1 transcript
components (28). In all six replicates, the minor allele was asso-
ciated with relatively lower usage of the second of the two 3′ ac-
ceptor sites (Fig. 3e): on average, 3.5% of transcripts had the
shorter exon 2 with the minor allele compared with 6.4% with
the major allele (paired t-test, P = 0.02). This pattern corre-
sponded to what was seen in the TCGA RNA-seq data of the tu-
mors, validating the functional effect of rs10424178 at the locus.
Discussion
The majority of disease raSNPs are in noncoding regions of the
genome (1), and these noncoding raSNPs are presumed to influ-
ence regulation of nearby genes. Here, we show that six breast
cancer raSNPs are associated with differential isoform expres-
sion of seven nearby genes in breast tumors. At five of these
loci, the top splicing QTL SNPs are also in high LD with the top
breast cancer associated SNPs. Our results suggest that regulation
of alternative splicing is perhaps nearly as important asmechan-
ism in affecting breast cancer susceptibility as regulation of
overall gene expression: there are eight eQTLs that have been
reported in breast tissue with these same breast cancer risk
loci (4,7).
Current pipelines for discerning the functional effects of
GWAS raSNPs focus on eQTL analyses and searching for asso-
ciated potential causal variants within coding, transcriptional
start site or enhancer regions using systematic annotation of
the genome for these sites (2,4,6–8,29–31). The findings of this
study suggest that splicing QTL analyses, as outlined here,
should be included to help illuminate the function of raSNPs
and that systematic annotation of genomic regions crucial for
splicing will be important in interpreting the results from
GWAS. Careful examination of putative associations is essential
to determine that an apparent splicing QTL effect is not an arti-
fact of mapping error or bias in RNA-sequencing data. Minigene
splicing reporter assays can confirm the splicing effects of the
predicted causal SNPs in vitro, much as luciferase reporter assays
can confirm the effects of predicted causal SNPs in enhancer
regions.
In addition to uncovering causal SNPs, splicing QTL associa-
tions can help clarify which candidate gene affects breast cancer
risk. For example, rs8170 is in LD with SNPs, which lead to
missense variants in ANKLE1 (6), but our analyses implicate
BABAM1 as the causal gene at this locus. This result is consistent
with the known interaction of BABAM1with BRCA1, andwith the
fact that rs8170 modifies the risk of BRCA1mutation carriers (32).
Furthermore, beyond identifying the candidate gene, the splicing
QTL associations implicate a particular exon or domain of that
gene as important in breast cancer risk. For example, not simply
the BABAM1 gene but an extra 38 base pairs of its 5′ untranslated
region is associated with increased breast cancer risk. Similarly,
two fewer amino acids in the sixth exon of the STXBP4 gene are
associated with increased breast cancer risk. Additional experi-
ments examining the effects of the particular transcripts we
identified to be associated with breast cancer risk should
enhance our understanding of breast cancer susceptibility.
We also developed an approach that compares the posterior
probability of the causal SNPs for the expression phenotype
with the breast cancer phenotype. Previous studies have also ex-
amined the likelihood that the causal SNP for an expression
phenotype is the same as that for a disease trait (33). Ourmethod
is similar to the approach of Giambartolomei et al. (34) that calcu-
lates the posterior probability of the same SNP being causal for
the gene expression and disease risk locus. However, ourmethod
is different in that it assumes that there is both a real gene
expression association and disease association at the locus and
that the only two possibilities are that they are due to the same
causative SNP versus different causative SNPs. In contrast, Giam-
bartolomei et al. consider a wider range of possibilities including
ones that do not have an expression association or disease asso-
ciation at the locus. As we started with loci that had been vali-
dated as GWAS hits for breast cancer and with a stringent FDR
for association for gene expression, the priors of no association
for either of these were not valid. Our approach was limited by
the P-values at some of the loci that were available from GAME-
ON. In particular, for the loci defined by rs11552449 and rs8170,
the GWAS signals in the GAME-ON dataset are in the range of
P-values of 0.01 to 0.001, which is likely insufficient to draw con-
clusions about the co-localization of the GWAS signal. As larger
datasets with more comprehensive SNP coverage become avail-
able, the other loci may produce clearer results.
Our study has several limitations. First, we used breast tumor
tissue, rather than normal tissue, to identify putative splicing
QTLs among the breast cancer raSNPs. A challenge in eQTL ana-
lyses has been using tumor tissue, of which there is much more
available expression data, to identify these effects in the face of
the acquired somatic genetic and epigenetic changes that occur
within tumors. Methods have been developed to adjust eQTL
analyses performed in tumor tissues for certain somatic altera-
tions, including copy number and methylation status (4). These
Table 2. Overlap of the posterior probabilities of the splicing QTL and case–control association statistics based on cumulative probability of case–
control association of >0.95
Target event Best P-value for breast
cancer from GAME-ON
Total number
of SNPs
Number of SNPs to
reach 0.95 probability
case–control
Splicing QTL
cumulative probability
Locus 1 STXBP4 5.2 × 10−5 908 54 0.99
Locus 2 DCLRE1B 2.0 × 10−3 705 337 0.99
Locus 2 PHTF1 705 337 >0.99
Locus 3 BABAM1* 5.1 × 10−3 588 452 >0.99
Locus 4 SRGAP2D 4.0 × 10−8 37 3 4.3 × 10−9
Locus 5 PEX14-exon7 8.3 × 10−4 537 90 0.60
Locus 5 PEX14-transcript uc001afk 537 90 0.97
Locus 6 RAD51L1-exon15 6.9 × 10−11 1151 11 9.2 × 10−8
Locus 6 RAD51L1-transcript uc001xkf 1151 11 0.29
*P-value for BABAM1 was obtained from the ER-negative analysis from GAME-ON, because this locus was identified by a GWAS for ER-negative breast cancer.
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factors are well understood to affect overall gene expression, but
their effects on alternative splicing patterns are, to date, less well
understood and more difficult to quantify. However, it is becom-
ing clear that methylation of splice sites can lead to variation in
alternative splicing (35) and that intragenic translocation events
can affect exon inclusion or exclusion, for example in small cell
lung cancer (36). It remains possible that these or other recurrent
somatic changes, such as somatic mutations affecting splicing
(14), could affect alternative splicing patterns in ways unmeas-
ured in our analyses. While these somatic changes may blur
themechanism connecting a raSNP to its associated change in al-
ternative splicing, the associations should remain valid: for ex-
ample, the association between a raSNP and exon exclusion
might in fact be dictated by its association with an intragenic
translocation event,withmethylation of a splice site or as, initial-
ly hypothesized, with the splicing event itself. Repeating splicing
QTL analyses in normal tissues as they become available, for ex-
ample with the development of the Genotype-Tissue Expression
database (37), will be instructive. However, ultimately, functional
validation of the impact of the genetic variant on the alternative
splicing pattern in an in vitro setting, as we performed with the
rs8170-BABAM1 association, is necessary to confirm the alterna-
tive splicing changes observed in any tissue.
A second limitation is that we limited our assembled tran-
script data to those produced by TCGA, namely using one tran-
script definition (UCSC) and one method of transcript assembly
(RSEM), though differentmethods are known to produce different
results (19). By requiring associations identified through whole-
transcript reconstruction to be supported by the focused tests
of exons and junctions, we eliminated some of the erroneous as-
sociations caused by transcript assembly. Nonetheless, we found
transcript reconstruction valuable, as it hinted at situations
where whole transcripts, rather than just exons or splice sites,
were implicated in breast cancer risk (RAD51L1). Third, we have
shown that mapping bias has the potential to generate false-
positive results. While we removed all identified problematic as-
sociations, it remains possible that there are unknown variants
in the exons and junctions generating unmeasured bias. Fourth,
wenote that the fact that a raSNP is associatedwith transcript ex-
pression does not mean its effect on breast cancer risk is
mediated through that transcript. In fact, wewere able to exclude
this possibility at one locus (SRGAP2D). While we attempted to
use information about association with breast cancer risk at the
loci to determinewhich splicing QTLswere likely to be connected
to breast cancer, functional studies are necessary to confirm the
link between change in expression pattern and cancer risk.
In summary, we have identified seven novel associations be-
tween SNPs discovered by GWAS for breast cancer and alterna-
tively spliced isoforms of genes in cis, five of which are
consistent with mediating the association between raSNP and
breast cancer risk. These splicing QTL associations help identify
likely causal SNPs and candidate genes and also implicate
specific alternatively spliced variants of those genes thatmediate
the effect on breast cancer susceptibility. Our results suggest that
SNPs affecting alternative splicing may play an important role in
breast cancer and possibly other complex genetic traits.
Methods
Germline genotypes and imputation
We downloaded the Affymetrix SNP6.0 germline genotypes from
TCGA (http://cancergenome.nih.gov; date of download 17 De-
cember 2012). To obtain genotypes for the breast cancer raSNPs
thatwere not directly genotyped in TCGA, aswell as other region-
al SNPs for fine-mapping, we phased using Shapeit V2 (38) and
imputed to the 1000 Genomes phase 1 V3 reference panel (39)
using IMPUTE2 (40). We used the imputed ‘dosage’ values (that
is, themeans of the distribution of imputed genotypes) in associ-
ation analyses, which allows for uncertainty about the true geno-
type to be incorporated into the association test (41). All 75 breast
cancer raSNPs were either directly genotyped in TCGA or had an
INFO score of ≥0.5.
Splicing QTL association analyses
All statistical analyses were performed with the R programing
language V2.15.3. We divided ER-positive (N = 358) and ER-nega-
tive (N = 109) tumors based on ER-status in the TCGA clinical
data. We performed all analyses on ER-positive and ER-negative
tumors separately.
We downloaded the Level 3 TCGA RNA-seq data (http://
cancergenome.nih.gov; date of download 30 December 2013) list-
ing the RPKM values and raw reads (used for DEXSeq analysis) for
each defined exon counting bin, number of reads mapping to
each defined exon–exon junction and RSEM expression estimates
for each annotated gene and transcript. We rank-normalized the
RPKM values within each exon counting bin, replacing each
RPKM value with its fractional rank (that is, its position in the
ordered array of all values divided by the total number of values)
and transforming that rank onto the standard normal distribu-
tion (42). For junction analysis, we adjusted the raw reads value
for the number of total reads per sample to obtain RPM values
and then rank-normalized these values according to the same
method. For transcript analysis, we similarly rank-normalized
the RSEM values for the reconstructed transcripts.
For each linear regression analysis (exon, junction and tran-
script), we adjusted for the overall expression of the gene, genetic
ancestry using the first three principal components identified
using EIGENSTRAT (43) on the genotypes of all TCGA samples
and global expression variability using the first three factors
identified using PEER analysis (16,17) on the log2 (RPKM + 0.25)
values of exons from the entire TCGA RNA-seq dataset (on ER-
positive and ER-negative tumors separately). For both principal
component analysis and PEER factor analysis, the first identified
principal component or factor explained the vast majority of the
variance of the samples, and we chose to use the first three as
covariates as there was a subsequent leveling off in proportion
of variance explained (Supplementary Material, Fig. S3).
For exon analysis, we tested the association of each raSNP
with each exon of each gene containing two ormore exonswithin
±500 kB:
RPKMexoni ¼ β0 þ β1gþ β2
Xn
j¼1
RPKMexonj
0
@
1
A RPKMexoni
2
4
3
5
þ β3PC1þ β4PC2þ β5PC3þ β6K1þ β7K2þ β8K3;
where RPKMexoni is the rank-normalized RPKM for the tested
exon, g is the genotype at the raSNP (the dosage value where im-
puted, ranging from 0 to 2), n is the number of exons in the gene,
PC1 through PC3 are the first three principal components and K1
through K3 are the first three factors identified through PEER
(16,17). In the exon analysis, when we adjusted for overall gene
expression, we subtracted the RPKM of the tested exon so as
not to diminish the power of the test in genes with very few
exons, where the overall gene expression may be strongly corre-
lated with the expression of the tested exon. For junction
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analysis, we tested the association of each raSNPwith each exon–
exon junction within ±500 kB:
RPMjunction ¼ β0 þ β1gþ β2RSEMgene þ β3PC1þ β4PC2þ β5PC3
þ β6K1þ β7K2þ β8K3:
For transcript analysis, we tested the association of each
raSNP with each transcript of each gene with two or more anno-
tated transcripts within ±500 kB, excluding transcripts that had
zero expression in >25% of samples:
RSEMtranscript ¼ β0 þ β1gþ β2RSEMgene þ β3PC1þ β4PC2þ β5PC3
þ β6K1þ β7K2þ β8K3:
We used the DEXSeq R Bioconductor software package V1.8.0
(18) to test for differential exon expression between genotypes
using raw exon counts and the negative binomial distribution.
For dispersion estimates in association tests, given the number
of samples, we did not apply exon sharing with fitDispersion-
Function(), instead using the dispersion parameter of each exon
calculated independently.We used the first ten principal compo-
nents from EIGENSTRAT as covariates. Supplementary Material,
Figure S2 was obtained using the plotDEXSeq() function of the
DEXSeq package.
Evaluation for mapping bias
To assess for evidence ofmapping bias, we downloaded the Level
1 RNA-seq BAM files for the 358 ER-positive tumorswithmatched
germline genotypes from TCGA (date of download 7 May 2014).
We identified all SNPs from1000 Genomes phase 1V3 (39) or Hap-
Map phase 2 (44) that were in LD with the index SNP with r2 > 0.1
in the European (1000 Genomes) or CEU (HapMap) populations
and lay within a site (exon or junction) found to be associated
with risk genotype. For each relevant association, we counted
all reads mapping to the site of interest excluding reads that
mapped to those SNPs and recalculated the association with
the raSNP genotype, adjusting for overall expression of the gene
and genetic ancestry.
Splicing QTL fine-mapping
For the 358 ER-positive tumors, we obtained the genotypes of all
SNPs from 1000 Genomes phase 1 V3 that were within ±500 kB of
each index raSNP that had been identified as a splicing QTL, that
hadminor allele frequency of >0.001 in TCGA samples and, if im-
puted as described previously, that had an INFO score of >0.5. We
then calculated the P-value for the association of each of these
SNPs with the exon, junction or transcript expression that we
had identified as being most significantly associated with the
index raSNP. We used the LocusZoom software (23) to generate
plots of the splicing QTL P-values against genomic position, col-
ored by LD r2 as calculated from the European population in 1000
Genomes.We usedHuman Splicing Finder V2.4.1 (25) to annotate
alternative splice sites and branch point sequences.We searched
for P-values for breast cancer risk association of SNPs in the
GAME-ONmeta-analysis of breast cancer risk case–control stud-
ies (27); if data for the SNP of interest were not available, we used
the SNP with the highest r2 with the index SNP in the European
population in 1000 Genomes. Figures 2c and 3c and c were ob-
tained using the UCSC Genome Browser (24).
Evaluating overlap of GWAS and splicing QTL signal
We first calculated the posterior probabilities that each SNPat the
locus was the causal SNP for case–control association. We then
repeated this process for the splicing QTL signal. For the case–
control association, we downloaded all of the association statis-
tics from the 1MB region around the index GWAS SNP from the
GAME-ON website (http://gameon.dfci.harvard.edu). We merged
the SNP list between the splicing QTL association analysis,
which had been imputed to 1000 Genomes (39) and the case–con-
trol association, which had been imputed to Hapmap version II
(44), and generated a list of overlap SNPs. To calculate the poster-
ior probabilities for each SNP in the dataset being the causal SNP,
we used a modification of the approach we have previously de-
veloped (45). We started with the observed vector Z of z scores
from the case–control association test for each of the SNPs and
the observed LD matrix Σ, which includes the elements rij for
each pair of SNPs where r is the LD coefficient where i and j re-
present individual SNPs from the list of n SNPs at the locus.
For each SNP, i, we calculated another matrix Mi whose ele-
ments μj are equal to zi × rij, which are the expected z statistics as-
suming that SNP i is causal (46). We then calculated the
likelihood, ‘i, of SNP i being the causal SNP conditional on the ob-
served vector Z, the expected vector M and the observed matrix,
Σ, using the inverse of the multivariate normal distribution:
‘i ¼ Φ1ðZ; M; ΣÞ: We repeated this process for each SNP, getting
a new vector ‘ of elements ‘i: The posterior probability Pi of
each SNP i is calculated as follows:
Pi ¼
liPn
j¼1 lj
;
where n is the number of elements in ‘:
We repeated this analysis for the splicing QTL analysis. To
derive Z scores for the SNPs from the splicingQTL analysis,we cal-
culated the Z statistics basedon an inverse normal transformation
from P-values derived from the linear regressionmodels and used
the signs from the β coefficients from the model.
Finally, to determine the overlap between the two sets of sig-
nals, we ordered the posterior probabilities from the case–control
analysis from highest to lowest. We then identified the minimal
number of SNPs required to produce a cumulative posterior prob-
ability of >0.95 of having the causal variant. If the cumulative
sum of the posterior probability of the GWAS was <0.05 when
the cumulative sum of the posterior probability of the splicing
QTL association was >0.95, we concluded that the two associa-
tions were likely to be due to a different causal variant.
Minigene splicing reporter assay
Wesynthesized two sequences corresponding to BABAM1 exon 2,
50 base pairs of flanking 3′ intronic sequence and 100 base pairs
of flanking 5′ intronic sequence, one with the major (C) and one
with theminor (T) allele of rs10424178, with an upstreamSalI and
a downstream XbaI restriction enzyme site (purchased from IDT
DNA). We subcloned these sequences into the RHCglo minigene
splicing reporter construct (28) by SalI and XbaI restriction en-
zyme digest and ligation. Both SNP variation subcloneswere veri-
fied by sequencing.
We then plated HEK293T cells at 1 × 106 cells/60-mm culture
dish in 4 ml growth medium (DMEM with 10% fetal bovine
serum, 1% penicillin–streptomycin and 1% l-glutamine; GIBCO
Life Technologies). Twenty-four hours after plating, we transfected
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cultures with 1 μg of the minigene plasmid using Lipofectamine
2000 (Life Technologies). We extracted total RNA 24 h post-trans-
fection by mirVana miRNA Isolation Kit (Life Technologies). We
performed RT–PCR on 1 µg of total extracted RNA to generate
cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). We per-
formed PCR on 200 ng of the generated cDNA using the MyTaq
RedMix (Bioline). The upstreamprimerwas RSV5U, and the down-
stream primer was TNIE4 as previously described (28). PCR pro-
ducts were subject to electrophoresis on a 3% agarose gel and
imaged and quantified by ChemiDoc XRS+ (Bio-Rad).
Supplementary material
Supplementary Material is available at HMG online.
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